What is Imaginostics?
Imaginostics specializes in pioneering non-invasive diagnostic solutions that leverage advanced quantitative imaging biomarkers. Their technology enhances the understanding of health and disease by integrating seamlessly with existing MRI scanners, enabling detailed visualization of vasculature, comprehensive health assessments, and early disease detection. The company is actively engaged in pre-clinical and clinical research across critical fields such as neuroscience, oncology, and cardiology, and is keen on forging strategic partnerships with academic institutions to further its mission of advancing patient care through safe and effective imaging technologies.
How much funding has Imaginostics raised?
Imaginostics has raised a total of $6.6M across 3 funding rounds:
Multiple Rounds
$6.6M
Private Equity (2026): $726K, investors not publicly disclosed
Private Equity (2026): $5.4M, investors not publicly disclosed
Private Equity (2026): $500K, investors not publicly disclosed
What's next for Imaginostics?
The substantial enterprise-level funding positions Imaginostics for significant scaling and further research and development. This strategic investment is expected to accelerate the company's efforts in clinical validation and market penetration, potentially leading to broader adoption of their advanced diagnostic tools. Future growth will likely focus on expanding research collaborations and commercializing their technology to impact patient outcomes across multiple therapeutic areas.
See full Imaginostics company page
